Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPHI China Pharma	$1.40 +1.4%	$1.67	$1.20 ▼ $3.35	$4.57M	0.87	105,719 shs	23,973 shs
ORGS Orgenesis	$1.00 +4,445.5%	$0.89	$0.00 ▼ $7.50	$4.80M	0.44	7,109 shs	267 shs
SPRB Spruce Biosciences	$7.60 -4.4%	$7.25	$0.06 ▼ $0.61	$4.27M	2.43	802,052 shs	1,625 shs
TMBR Timber Pharmaceuticals		$1.87	$0.32 ▼ $3.39	$1.21M	0.03	511,937 shs	26,307 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPHI China Pharma	-2.82%	-2.13%	-27.52%	-31.00%	-93.64%
ORGS Orgenesis	-78.00%	-31.25%	-97.80%	-98.90%	+2,199,900.00%
SPRB Spruce Biosciences	-3.05%	-11.17%	-9.71%	+65.63%	-78.37%
TMBR Timber Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	1.6057 of 5 stars	0.0	3.0	0.0	4.4	1.7	0.0	0.0
SPRB Spruce Biosciences	1.6897 of 5 stars	3.0	3.0	0.0	0.0	0.6	1.7	0.6
TMBR Timber Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPHI China Pharma	0.00	N/A	N/A	N/A
ORGS Orgenesis	0.00	N/A	N/A	N/A
SPRB Spruce Biosciences	2.00	Hold	$131.25	1,626.97% Upside
TMBR Timber Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPHI China Pharma	$4.40M	1.04	N/A	N/A	$0.70 per share	2.00
ORGS Orgenesis	$662K	7.25	N/A	N/A	($6.58) per share	-0.15
SPRB Spruce Biosciences	$4.91M	0.87	N/A	N/A	$1.88 per share	4.04
TMBR Timber Pharmaceuticals	$80K	0.00	N/A	N/A	$1.79 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPHI China Pharma	-$3.08M	N/A	0.00	∞	N/A	-85.56%	-63.93%	-31.42%	N/A
ORGS Orgenesis	-$55.36M	N/A	0.00	∞	N/A	-3,827.81%	N/A	-130.18%	11/11/2025 (Estimated)
SPRB Spruce Biosciences	-$47.92M	-$99.25	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	11/10/2025 (Estimated)
TMBR Timber Pharmaceuticals	-$19.38M	N/A	0.00	N/A	N/A	N/A	-511.45%	-180.93%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A
TMBR Timber Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPHI China Pharma	0.22	0.79	0.26
ORGS Orgenesis	N/A	0.07	0.07
SPRB Spruce Biosciences	0.01	5.36	5.36
TMBR Timber Pharmaceuticals	N/A	0.50	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPHI China Pharma	N/A
ORGS Orgenesis	22.56%
SPRB Spruce Biosciences	91.71%
TMBR Timber Pharmaceuticals	3.62%

Insider Ownership

Company	Insider Ownership
CPHI China Pharma	17.32%
ORGS Orgenesis	5.66%
SPRB Spruce Biosciences	6.90%
TMBR Timber Pharmaceuticals	1.61%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPHI China Pharma	250	3.26 million	15.92 million	Not Optionable
ORGS Orgenesis	150	4.80 million	4.53 million	No Data
SPRB Spruce Biosciences	20	562,000	37.54 million	Optionable
TMBR Timber Pharmaceuticals	9	3.43 million	3.38 million	Not Optionable

TMBR, CPHI, ORGS, and SPRB Headlines

Recent News About These Companies

MSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sources

January 31, 2025 | nypost.comN

Timber back in Dutch squad and twin brother also called up

August 30, 2024 | reuters.com

Rare disease drug from LEO's Timber felled by failed study

August 25, 2024 | pharmaphorum.comP

Can timber construction overcome its growing pains?

May 13, 2024 | reuters.com

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting

March 10, 2024 | businesswire.com

Timber Pharmaceuticals Announces Official Name Change

January 28, 2024 | msn.com

Timber Pharmaceuticals Inc (TMBRQ)

January 13, 2024 | uk.investing.com

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

November 29, 2023 | finance.yahoo.com

NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)

November 29, 2023 | finance.yahoo.com

Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American

November 28, 2023 | tmcnet.com

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

November 28, 2023 | finance.yahoo.com

MVST, FBIO and VTVT among mid-day movers

November 21, 2023 | seekingalpha.com

Timber Pharmaceuticals files for Chapter 11 in wake of failed merger

November 17, 2023 | msn.com

Timber Pharma slips ahead of shareholder vote on merger

November 16, 2023 | msn.com

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

September 18, 2023 | finance.yahoo.com

HC Wainwright Downgrades Timber Pharmaceuticals

August 29, 2023 | 247wallst.com

HC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)

August 28, 2023 | msn.com

Timber Pharmaceuticals rockets as it agrees to a takeover

August 21, 2023 | thepharmaletter.comT

TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders

August 21, 2023 | benzinga.com

Dow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike Higher

August 21, 2023 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMBR, CPHI, ORGS, and SPRB Company Descriptions

China Pharma NYSE:CPHI

$1.40 +0.02 (+1.45%)

Closing price 03:59 PM Eastern

Extended Trading

$1.40 0.00 (-0.36%)

As of 05:49 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Orgenesis NASDAQ:ORGS

$1.00 +0.98 (+4,445.45%)

As of 12:04 PM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Spruce Biosciences NASDAQ:SPRB

$7.60 -0.35 (-4.40%)

As of 08/26/2025

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Timber Pharmaceuticals NYSE:TMBR

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time